Thomas Triomphe, executive vice-president, head of vaccines, Sanofi, said the company's growth in China, especially in vaccines, is largely due to the open, international business environment in Shenzhen city and Pingshan district.

"We'll introduce more innovative products and preventive solutions to support the public health system and meet the disease prevention needs of the Chinese. We hope this will also contribute to the economic growth of Shenzhen and the Greater Bay Area," he said.

Sanofi and the Shenzhen government had previously in 2019 signed a memorandum of understanding regarding a strategic cooperation in vaccine innovation.

In 2021, the two parties established the GBA International Vaccine Innovation Center in Pingshan district.